Zymeworks Common Stock Stock Performance
| ZYME Stock | USD 13.88 0.11 0.79% |
Zymeworks Common has a performance score of 3 on a scale of 0 to 100. The firm maintains a market beta of 0.98, which attests to possible diversification benefits within a given portfolio. Zymeworks Common returns are very sensitive to returns on the market. As the market goes up or down, Zymeworks Common is expected to follow. Zymeworks Common Stock right now maintains a risk of 3.63%. Please check out Zymeworks Common Stock value at risk, as well as the relationship between the skewness and day median price , to decide if Zymeworks Common Stock will be following its historical returns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Zymeworks Common Stock are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Zymeworks Common may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
Actual Historical Performance (%)
One Day Return (0.79) | Five Day Return 3.58 | Year To Date Return (6.09) | Ten Year Return 6.77 | All Time Return 6.77 |
1 | Zymeworks Announces Participation in Upcoming Investor Conferences - Yahoo Finance | 10/29/2024 |
2 | Zymeworks Hits New 12-Month High Should You Buy | 11/14/2024 |
3 | Acquisition by Kenneth Galbraith of 215000 shares of Zymeworks Common at 8.0 subject to Rule 16b-3 | 11/20/2024 |
4 | Acquisition by Gallagher Neil of 31000 shares of Zymeworks Common at 13.06 subject to Rule 16b-3 | 12/10/2024 |
5 | Zymeworks adjusts non-employee director pay | 12/11/2024 |
6 | Zymeworks Is In A Good Position To Deliver On Growth Plans | 12/13/2024 |
7 | Acquisition by Ecor1 Capital, Llc of 298818 shares of Zymeworks Common at 13.5289 subject to Rule 16b-3 | 12/19/2024 |
8 | Acquisition by Ecor1 Capital, Llc of 704488 shares of Zymeworks Common at 14.0776 subject to Rule 16b-3 | 12/20/2024 |
9 | Acquisition by Ecor1 Capital, Llc of 251502 shares of Zymeworks Common at 14.2508 subject to Rule 16b-3 | 12/23/2024 |
10 | Acquisition by Ecor1 Capital, Llc of 11958 shares of Zymeworks Common at 14.1241 subject to Rule 16b-3 | 12/24/2024 |
11 | Acquisition by Ecor1 Capital, Llc of 16692 shares of Zymeworks Common at 14.3804 subject to Rule 16b-3 | 12/26/2024 |
12 | Acquisition by Ecor1 Capital, Llc of 101659 shares of Zymeworks Common at 14.4914 subject to Rule 16b-3 | 12/27/2024 |
13 | Acquisition by Ecor1 Capital, Llc of 58988 shares of Zymeworks Common at 14.4661 subject to Rule 16b-3 | 12/30/2024 |
14 | Acquisition by Ecor1 Capital, Llc of 146501 shares of Zymeworks Common at 14.5695 subject to Rule 16b-3 | 12/31/2024 |
15 | Acquisition by Ecor1 Capital, Llc of 157880 shares of Zymeworks Common at 14.7796 subject to Rule 16b-3 | 01/02/2025 |
16 | Disposition of 11110 shares by Smith Jeffrey T L of Zymeworks Common at 14.9241 subject to Rule 16b-3 | 01/06/2025 |
17 | Paul Andrew Moore Sells 21,200 Shares of Zymeworks Inc. Stock | 01/07/2025 |
18 | Acquisition by Kenneth Galbraith of 192000 shares of Zymeworks Common subject to Rule 16b-3 | 01/10/2025 |
19 | Acquisition by Ecor1 Capital, Llc of 74125 shares of Zymeworks Common at 13.3946 subject to Rule 16b-3 | 01/13/2025 |
20 | Acquisition by Ecor1 Capital, Llc of 54500 shares of Zymeworks Common at 13.5645 subject to Rule 16b-3 | 01/14/2025 |
21 | Acquisition by Ecor1 Capital, Llc of 029 shares of Zymeworks Common at 14.0068 subject to Rule 16b-3 | 01/15/2025 |
| Begin Period Cash Flow | 400.9 M |
Zymeworks |
Zymeworks Common Relative Risk vs. Return Landscape
If you would invest 1,317 in Zymeworks Common Stock on October 21, 2024 and sell it today you would earn a total of 71.00 from holding Zymeworks Common Stock or generate 5.39% return on investment over 90 days. Zymeworks Common Stock is currently generating 0.1487% in daily expected returns and assumes 3.6322% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Zymeworks, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zymeworks Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zymeworks Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zymeworks Common Stock, and traders can use it to determine the average amount a Zymeworks Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.041
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ZYME | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.63 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Zymeworks Common is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zymeworks Common by adding it to a well-diversified portfolio.
Zymeworks Common Fundamentals Growth
Zymeworks Stock prices reflect investors' perceptions of the future prospects and financial health of Zymeworks Common, and Zymeworks Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zymeworks Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.83) % | ||||
| Operating Margin | (2.14) % | ||||
| Current Valuation | 679.07 M | ||||
| Shares Outstanding | 68.88 M | ||||
| Price To Earning | (2.36) X | ||||
| Price To Book | 2.63 X | ||||
| Price To Sales | 15.49 X | ||||
| Revenue | 76.01 M | ||||
| Gross Profit | (62.46 M) | ||||
| EBITDA | (120.7 M) | ||||
| Net Income | (118.67 M) | ||||
| Cash And Equivalents | 241.83 M | ||||
| Cash Per Share | 4.18 X | ||||
| Total Debt | 26.72 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 3.29 X | ||||
| Book Value Per Share | 5.27 X | ||||
| Cash Flow From Operations | (118.3 M) | ||||
| Earnings Per Share | (1.48) X | ||||
| Market Capitalization | 963.6 M | ||||
| Total Asset | 580.88 M | ||||
| Retained Earnings | (677.44 M) | ||||
| Working Capital | 357.16 M | ||||
About Zymeworks Common Performance
By analyzing Zymeworks Common's fundamental ratios, stakeholders can gain valuable insights into Zymeworks Common's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zymeworks Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zymeworks Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.23) | (0.24) |
Things to note about Zymeworks Common Stock performance evaluation
Checking the ongoing alerts about Zymeworks Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zymeworks Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zymeworks Common had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with loss before overhead, payroll, taxes, and interest of (62.46 M). | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Zymeworks Common has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Acquisition by Ecor1 Capital, Llc of 54500 shares of Zymeworks Common at 13.5645 subject to Rule 16b-3 |
- Analyzing Zymeworks Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zymeworks Common's stock is overvalued or undervalued compared to its peers.
- Examining Zymeworks Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zymeworks Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zymeworks Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zymeworks Common's stock. These opinions can provide insight into Zymeworks Common's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |